Unlocking the Genetic Code: Advances and Future Directions in Vision Disorder Research

Vishal Biswas, M. Optom

Assistant Professor and Program Coordinator, Ph.D. Scholar, Department of Optometry, School of Allied Health Sciences; Noida International University

 

Overview of Vision Disorders and Their Genetic Basis

Vision disorders, causing global visual impairment and blindness, range from common conditions like myopia to rare diseases such as retinitis pigmentosa. Modern genomic research suggests that both have a strong genetic basis, involving multiple genes and their association with environmental factors.⁽¹⁾

Genetic Underpinnings of Common Vision Disorders

Common vision disorders, such as myopia, hyperopia, and astigmatism, arise from complex genetic and environmental interactions. Key genes like ANTXR2, KCNQ5, and PDE11A are linked to these conditions. ⁽²⁾ Genetic factors vary across populations, underscoring the necessity for diverse research to understand these disorders fully. ⁽³⁾

Genetic Basis of Rare Vision Disorders

In comparison with common disorders, rare vision disorders often exhibit clear inheritance patterns and distinct genetic mutations. Retinitis pigmentosa, for instance, is defined by mutations in approximately 60 distinct genes essential for photoreceptor health and function. These mutations lead to progressive vision loss due to photoreceptor cell death. Leber congenital amaurosis (LCA), mostly caused by mutations in genes like RPE65, has an autosomal recessive inheritance pattern, leading to significant visual impairment since birth. ⁽⁴⁾

Recent Breakthroughs in Genetic Research

In the past several decades, we have seen significant innovations in genetic research related to vision disorders. One significant breakthrough is the application of next-generation sequencing (NGS), which allows for rapid and comprehensive genomic testing of numerous genes involved with both common and rare vision conditions. This technology has revolutionised the diagnosis of inherited retinal diseases by enabling the identification of pathogenic variants rapidly. ⁽⁵⁾

Furthermore, large-scale genome-wide association investigations (GWAS) have found several genetic loci linked with myopia and other refractive errors, extending our comprehension of the polygenic nature of common visual problems. ⁽⁵⁾ This evolving knowledge supports more effective screening measures and personalised treatment plans.

Gene Therapy: Advances and Future Directions

Gene therapy has emerged as a promising approach to treating genetic vision disorders. Luxturna® (voretigene neparvovec) has made headlines as the first FDA-approved gene therapy for patients with RPE65-related LCA, demonstrating significant improvements in visual acuity. ⁽⁶⁾ Clinical studies are additionally underway for other hereditary retinal disorders, targeting specific gene mutations while seeking to improve safety and efficacy. ⁽⁷⁾

Research is focusing on various innovative gene delivery methods and optimisation of treatment protocols, overcoming challenges such as managing inflammation responses and ensuring the long-term safety of therapies. ⁽⁷⁾ The exploration of CRISPR technology provides great opportunities for potential future interventions, aiming for precise corrections of genetic mutations at the DNA level. ⁽⁸⁾

Implications of Genetic Findings for Diagnosis and Treatment

Genetic research is transforming vision disorder management by identifying mutations for targeted therapies. ⁽⁹⁾ Genetic counselling plays a vital role, providing patients with crucial information for informed decisions about their conditions, risks, and family planning. ⁽¹⁰⁾

Conclusion

​Advancements in genetic research are enhancing our understanding of vision disorders, improving diagnostics, and driving personalised therapies. Ongoing studies and trials promise significant progress in addressing both common and rare conditions, leading to better vision outcomes globally.

*No conflict-of-interest present

*No Funding

 

References:

1. Singh M, Tyagi SC. Genes, and genetics in eye diseases: a genomic medicine approach for investigating hereditary and inflammatory ocular disorders. International journal of ophthalmology. 2018;11(1):117.
2. Simpson CL, Wojciechowski R, Oexle K, Murgia F, Portas L, Li X, Verhoeven VJ, Vitart V, Schache M, Hosseini SM, Hysi PG. Genome-wide meta-analysis of myopia and hyperopia provides evidence for replication of 11 loci. PloS one. 2014 Sep 18;9(9):e107110.
3. Seddon JM. Genetic and environmental underpinnings to age-related ocular diseases. Investigative ophthalmology & visual science. 2013 Dec 1;54(14):ORSF28-30.
4. Hull S, Mukherjee R, Holder GE, Moore AT, Webster AR. The clinical features of retinal disease due to a dominant mutation in RPE65. Molecular vision. 2016;22:626.
5. Tedja MS, Wojciechowski R, Hysi PG, Eriksson N, Furlotte NA, Verhoeven VJ, Iglesias AI, Meester-Smoor MA, Tompson SW, Fan Q, Khawaja AP. Genome-wide association meta-analysis highlights light-induced signaling as a driver for refractive error. Nature genetics. 2018 Jun;50(6):834-48.
6. Miraldi Utz V, Coussa RG, Antaki F, Traboulsi EI. Gene therapy for RPE65-related retinal disease. Ophthalmic genetics. 2018 Nov 2;39(6):671-7.
7. Maguire AM, Bennett J, Aleman EM, Leroy BP, Aleman TS. Clinical perspective: treating RPE65-associated retinal dystrophy. Molecular Therapy. 2021 Feb 3;29(2):442-63.
8. Nidhi S, Anand U, Oleksak P, Tripathi P, Lal JA, Thomas G, Kuca K, Tripathi V. Novel CRISPR–Cas systems: an updated review of the current achievements, applications, and future research perspectives. International journal of molecular sciences. 2021 Mar 24;22(7):3327.
9. Panikker P, Roy S, Ghosh A, Poornachandra B, Ghosh A. Advancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies. Frontiers in Medicine. 2022 Jul 15;9:906482.
10. Hui EK, Yam JC, Rahman F, Pang CP, Kumaramanickavel G. Ophthalmic genetic counselling: emerging trends in practice perspectives in Asia. Journal of Community Genetics. 2023 Feb;14(1):81-9.